Dopaminergic neurotransmission and cognitive decline in velocardiofacial syndrome
Withdrawn
- Conditions
- cognitive declinedementia10083624
- Registration Number
- NL-OMON31666
- Lead Sponsor
- Academisch Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Withdrawn
- Sex
- Not specified
- Target Recruitment
- 40
Inclusion Criteria
Possession of del 22q11.2
Premorbid IQ of above 70 en now below 55
Premorbid IQ below 55
Only for the intervention group: serious behavioural and/or refractory psychiatric problems to treatment so far
Exclusion Criteria
pregnancy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>In plasma (T0,3,6) : HVA, MHPG, VMA, prolactine, level AMPT, proline<br /><br>In urine (T0,6): HVA, MHPG, VMA, dopamine and norepinephrine, proline<br /><br>Genotype (DNA isolation T0): COMT Val/Met polymorphism, other COMT<br /><br>polymorphisms.<br /><br>COMT enzyme activity in erytrocytes or lymphocytes</p><br>
- Secondary Outcome Measures
Name Time Method <p>Extrapyridamal side effects; IQ; Dementia rating scales (DMR and DSDS);<br /><br>psychiatric symptomatology (PASSAD); behaviour checklists (ABCL and SGZ); IQ<br /><br>measurements with Wechsler IQ scales</p><br>